Enliven Therapeutics
ELVN
113 hedge funds and large institutions have $1.12B invested in Enliven Therapeutics in 2024 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 45 increasing their positions, 25 reducing their positions, and 11 closing their positions.
257% more call options, than puts
Call options by funds: $25K | Put options by funds: $7K
100% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 11
80% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 25
11% more funds holding
Funds holding: 102 → 113 (+11)
0.62% more ownership
Funds ownership: 100.95% → 101.57% (+0.62%)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
8% less capital invested
Capital invested by funds: $1.22B → $1.12B (-$101M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$45.1M |
| 2 |
Janus Henderson Group
London,
|
+$7.52M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$6.48M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.18M |
| 5 |
Pictet Asset Management
Carouge,
Switzerland
|
+$3.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$9.2M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$5.5M |
| 3 |
CCM
Cutter Capital Management
New York
|
-$5.31M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$4.26M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.89M |
ELVN Hedge Fund Activity: Q4 2024 in Review
113 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q4 2024, worth a combined $1.12B — down 8.3% from $1.22B a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ELVN positions and 11 closed out — a net gain of 11 holders — while 45 added to existing stakes and 25 trimmed.
The largest buyer was Polar Capital Holdings, adding an estimated $45.1M. The largest seller was Logos Global Management, cutting an estimated $9.2M.
- 113 institutional investors held Enliven Therapeutics (ELVN) as of Q4 2024, up from 102 in Q3 2024.
- Funds reported $1.12B of Enliven Therapeutics stock for Q4 2024, down 8.3% quarter-over-quarter.
- 22 funds opened new Enliven Therapeutics positions in Q4 2024 and 11 closed out, a net change of +11 holders.
- The largest Enliven Therapeutics buyer in Q4 2024 was Polar Capital Holdings, an estimated $45.1M added.
- The largest Enliven Therapeutics seller in Q4 2024 was Logos Global Management, an estimated $9.2M sold.
Based on aggregated 13F filings for Q4 2024.